Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 95

Sort by

Sort Order Select

Journal Articles

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Blood (2024) 144 (12): 1284–1289.

https://doi.org/10.1182/blood.2023023639

Published: 2024

Includes: Supplemental data

Journal Articles

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach

Blood (2023) 142 (8): 687–699.

https://doi.org/10.1182/blood.2022018818

Published: 2023

Includes: Supplemental data

Journal Articles

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Blood (2022) 140 (Supplement 1): 2326–2328.

https://doi.org/10.1182/blood-2022-160386

Published: 2022

Journal Articles

Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome

Karan Chohan, Saurabh Zanwar, Ronald Go, Jonas Paludo, Carrie A. Thompson, Asher Chanan-Khan, Sikander Ailawadhi, Thomas M. Habermann, Thomas E. Witzig, Morie A Gertz, Stephen M. Ansell, Shaji K Kumar, Rajiv K. Pruthi, William L. Nichols, Prashant Kapoor, Meera Sridharan, Jithma P. Abeykoon

Blood (2022) 140 (Supplement 1): 9363–9365.

https://doi.org/10.1182/blood-2022-168232

Published: 2022

Journal Articles

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Blood (2022) 140 (Supplement 1): 9470–9472.

https://doi.org/10.1182/blood-2022-159586

Published: 2022

Journal Articles

Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis

Ricardo D Parrondo, Lindsay Brooke Gardner, Mohamad Alhaj Moustafa, Vivek Roy, Taimur Sher, Ahsan Rasheed, Rahma M Warsame, Jeremy T. Larsen, Wilson I. Gonsalves, Taxiarchis Kourelis, Prashant Kapoor, Rafael Fonseca, Asher Chanan-Khan, Sikander Ailawadhi

Blood (2022) 140 (Supplement 1): 7237–7238.

https://doi.org/10.1182/blood-2022-169533

Published: 2022

Journal Articles

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Taimur Sher, Aneel Paulus, Dustin Chapin, Keisha Heslop, Asher Chanan-Khan, Vivek Roy

Blood (2022) 140 (Supplement 1): 4450–4451.

https://doi.org/10.1182/blood-2022-164656

Published: 2022

Journal Articles

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Sikander Ailawadhi, Ricardo D Parrondo, Aneel Paulus, Betsy Laplant, Victoria R. Alegria, Ashley Zimmerman, Dustin Chapin, Taimur Sher, Vivek Roy, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 9904–9905.

https://doi.org/10.1182/blood-2022-164667

Published: 2022

Journal Articles

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Ashley Zimmerman, Keisha Heslop, Dustin Chapin, Taimur Sher, Vivek Roy, Ahsan Rasheed, Aneel Paulus, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 9331–9332.

https://doi.org/10.1182/blood-2022-165377

Published: 2022

Journal Articles

Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study

Sikander Ailawadhi, Jay R. Hydren, Leyla Bojanini, Nathan W. Sweeney, Felicia Seng, Mizba Baksh, Ahsan Rasheed, Mays Abdulazeez, Meghna Ailawadhi, Keren George, Ricardo D Parrondo, Vivek Roy, Victoria R. Alegria, Pooja Advani, Rami Manochakian, Jason S. Starr, Taimur Sher, Jennifer M. Ahlstrom, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 7941–7942.

https://doi.org/10.1182/blood-2022-167005

Published: 2022

Journal Articles

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, John C. Byrd, Talha Munir, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Jennifer R. Brown, Anthony R. Mato, Stephan Stilgenbauer, Thomas Fehn, Paulo Andre P. de Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach

Blood (2022) 140 (Supplement 1): 7050–7052.

https://doi.org/10.1182/blood-2022-157060

Published: 2022

Journal Articles

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Blood (2022) 140 (Supplement 1): 10017–10019.

https://doi.org/10.1182/blood-2022-167181

Published: 2022

Journal Articles

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Sikander Ailawadhi, Ricardo D Parrondo, Gabriela Perez, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Ernesto Ayala, Patrick J O'Brien, Vivek Roy, Victoria R. Alegria, Ashley Zimmerman, Dustin Chapin, Stephanie Lanier, Carly Kasik, Schannon Bradley, Taimur Sher, Aneel Paulus, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 10165–10166.

https://doi.org/10.1182/blood-2022-165209

Published: 2022

Journal Articles

Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape

Karan Chohan, Jonas Paludo, Surendra Dasari, Jithma P. Abeykoon, Prashant Kapoor, Esteban Braggio, Michelle K. Manske, Aneel Paulus, Craig B. Reeder, Sikander Ailawadhi, Asher Chanan-Khan, Robert A. Kyle, Morie A Gertz, Anne J. Novak, Stephen M. Ansell

Blood (2022) 140 (Supplement 1): 9242–9243.

https://doi.org/10.1182/blood-2022-167543

Published: 2022

Journal Articles

Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance

Blood (2022) 140 (18): 1997–2000.

https://doi.org/10.1182/blood.2022017616

Published: 2022

Includes: Supplemental data

Journal Articles

Real-World Evidence on Shift in Treatment Practice and Adoption of Novel Agents for Patients with Chronic Lymphocytic Leukemia in the United States

Asher Chanan-Khan, Keri Yang, Sizhu Liu, Todd Zimmerman, Boxiong Tang, Sikander Ailawadhi

Blood (2021) 138 (Supplement 1): 5013.

https://doi.org/10.1182/blood-2021-148736

Published: 2021

Journal Articles

Productivity Loss and Indirect Costs Among Non-Hodgkin Lymphoma Patients and Their Caregivers

Keri Yang, Sizhu Liu, Debra Irwin, Elizabeth Packnett, Carolyn R. Lew, Virginia Noxon, Boxiong Tang, Asher Chanan-Khan

Blood (2021) 138 (Supplement 1): 4009.

https://doi.org/10.1182/blood-2021-148443

Published: 2021

Journal Articles

Real-World Treatment Patterns, Adherence and Healthcare Resource Utilization for Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Among Veterans in the United States

Keri Yang, Sizhu Liu, Boxiong Tang, Asher Chanan-Khan

Blood (2021) 138 (Supplement 1): 4079.

https://doi.org/10.1182/blood-2021-148716

Published: 2021

Journal Articles

Real-World Testing Patterns for Risk Assessment and Implications on the Adoption of Novel Therapeutics in Chronic Lymphocytic Leukemia: IGHV Mutation Status, FISH Cytogenetic, and Immunophenotyping

Asher Chanan-Khan, Keri Yang, Tom Liu, Todd Zimmerman, Boxiong Tang, Sikander Ailawadhi

Blood (2021) 138 (Supplement 1): 4078.

https://doi.org/10.1182/blood-2021-147955

Published: 2021

Journal Articles

Impact of Atrial Fibrillation on Cardiovascular and Economic Outcomes in Patients with Chronic Lymphocytic Leukemia

Anjana Mohan, Keri Yang, Sizhu Liu, Randall Dick, Boxiong Tang, Asher Chanan-Khan

Blood (2021) 138 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2021-148600

Published: 2021

NARROW

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape

Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance

Real-World Evidence on Shift in Treatment Practice and Adoption of Novel Agents for Patients with Chronic Lymphocytic Leukemia in the United States

Productivity Loss and Indirect Costs Among Non-Hodgkin Lymphoma Patients and Their Caregivers

Real-World Treatment Patterns, Adherence and Healthcare Resource Utilization for Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Among Veterans in the United States

Real-World Testing Patterns for Risk Assessment and Implications on the Adoption of Novel Therapeutics in Chronic Lymphocytic Leukemia: IGHV Mutation Status, FISH Cytogenetic, and Immunophenotyping

Impact of Atrial Fibrillation on Cardiovascular and Economic Outcomes in Patients with Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only